Risk of Age‐Related Ocular Diseases in Non‐Diabetic Adults With Obesity Using Glucagon‐Like Peptide 1 Receptor Agonists
Authors' conclusion
GLP-1RAs were associated with lower risks of multiple age-related ocular conditions in non-diabetic older adults.
Study context
- Population
- Non-diabetic, overweight or obese adults aged ≥60 years with an ophthalmic disease-naïve baselineafter matching
- Participants
- 68,536 participants
- Exposure
- GLP-1 RAs vs alternative weight-loss medications
- GLP-1RAsn = 34,268
- Alternative weight-loss medicationsn = 34,268reference
- Outcome
- Incident cataract, AMD, ocular hypertension, primary open-angle glaucoma (POAG) and dry eye syndrome (DES)
- Follow-up
- Up to 5 years
Methodological detailspropensity score-matched, 1:1 matching, TriNetX global research network
- Propensity score-matched
- 1:1 matching
- TriNetX global research network
Main finding
As reported in the abstract
Age-related ocular diseases · 5 years
GLP-1RAs vs Alternative weight-loss medicationsRelative risk (95% CI)
Cataract
0.45(0.40–0.50)
AMD
0.33(0.23–0.48)
Ocular hypertension
0.56(0.34–0.91)
POAG
0.50(0.32–0.78)
DES
0.36(0.31–0.42)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of Age‐Related Ocular Diseases in Non‐Diabetic Adults With Obesity Using Glucagon‐Like Peptide 1 Receptor Agonists. Diabetes Obes Metab. Published 8 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →